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β-globin gene on the transcriptional activity of keratinocytes. The
activity of pCAGS-lacZ was about 15 times greater than that of
pAGS-lacZ and that of pCAGGS was about two and six times
those of pCAGS-lacZ and pCMS-lacZ, respectively (Fig 1B).
The amount of transgene was measured semiquantitatively 24 h
after the introduction of various constructs. We introduced pAGS-
lacZ, pCAGS-lacZ, pCAGGS-lacZ, and pCMS-lacZ, and per-
formed PCR amplification of the lacZ gene. We also injected
phosphate-buffered saline as a control. The result showed no clear
differences among the band intensities of the PCR products
(Fig 2A), and the amounts of the transgene (lacZ) in the ker-
atinocytes into which these plasmids introduced could not reflect
a difference among the activities of the plasmids. We detected no
bands in the sample of phosphate-buffered saline. We sequenced
the PCR products and digested with appropriate restriction enzymes
to test for PCR specificity (data not shown).
Cheng et al (1993) carried out similar experiments using particle
bombardment to introduce genes, and showed that the CMV-IE
promoter was very active in keratinocytes. We also found that the
CMV-IE promoter in pCMS-lacZ exhibited very high activity
(Fig 1). We also evaluated the activities of the promoter from
genes that were specifically expressed in keratinocytes and found
that the K10 promoter in pK10Z showed the highest activity
(Fig 1A); however, the K10 promoter in pK10S-lacZ was still
weaker than the CMV-IE promoter in pCMS-lacZ. Our results
demonstrate that the CMV-IE promoter was superior to the other
simple promoters, with respect to the activity level. In an attempt
to take advantage of the highly active viral CMV-IE promoter, we
assayed the activity of pCAGS. This construct was tested using
several types of cell in culture; enhancement of expression was
observed in L and CHO cells, but not in F9 cells (Niwa et al, 1991).
The addition of CMV-IE enhancer increased β-gal expression in
keratinocytes in vivo 15-fold. The 39-flanking sequence of the
rabbit β-globin gene was used for the construction of expression
vectors in several groups and these vectors exhibited high levels of
production of the inserted gene in various cells (Niwa et al, 1991;
Karasuyama and Melchers, 1988). We also tested the activity of
pCAGGS-lacZ, in which 39-flanking sequence of the rabbit
β-globin gene was introduced into the 39-end of the lacZ gene,
resulting in a further 2-fold enhancement. We could not make
precise comparisons among pCAGGS-lacZ and the other constructs
because of different backbones, but pCAGGS-lacZ exhibited the
highest activity for all the constructs tested. We constructed an
interleukin-10 expression vector using this cassette, introduced it
into keratinocytes in vivo by direct injection of naked DNA, and
achieved systemic expression of transgenic interleukin-10 (Meng
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To the Editor:
In a recent issue of the journal, Hopkinson et al (1998) have
reported studies aimed at assessing the interaction potential of
BP180 with the α6 integrin subunit, and they raised concerns
about the consistency and validity of previous data published by
our and other groups on this subject. Because several statements
appear at best to be polemic due to the authors’ unwillingness to
thoroughly review work of other investigators, rather than
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et al, 1998). This study has provided useful information for
developing potential promoter/enhancer cassettes for keratinocyte
gene therapy using the direct injection of naked DNA method.
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addressing the potential complex mechanisms involved in the
assembly of hemidesmososmes, some clarifications are required.
These authors emphasize a first contradiction between their data
and our findings on page 1017, where it is stated that a fragment
of BP180, containing the complete cytoplasmic domain, the
transmembrane domain, and a short region of the extracellular
domain, does not autoactivate transcription of reporter genes in
yeast. In the authors’ interpretations, these results contradict our
findings, which indicated that a fragment of BP180 containing the
complete cytoplasmic domain without the transmembrane domain
cannot be used in the yeast-two hybrid assay because of autoactiv-
ation. It is obvious, however, that the cDNA clones of BP180 used
in these two studies cannot be directly compared. In addition, we
VOL. 112, NO. 5 MAY 1999 LETTERS TO THE EDITOR 831
have found that either by removing a segment of 66 amino acids of
the carboxy-terminal end of the cytoplasmic domain (the region
containing multiple glycine and cysteine residues; see Schaapveld
et al, 1998) or, as shown by Hopkinson et al (1998), by extending the
clone at the carboxy-terminal end, autoactivation can be avoided.
Thus, it is difficult to understand why Hopkinson et al conclude that
their data are inconsistent with our findings.
On page 1020, these authors further state that the idea that BP180
binds to α6 contradicts the recent conclusions by Sonnenberg et al.
While we have never disputed the binding of BP180 to α6, we
have only disagreed with the assumption formulated by Jones and
collaborators (Hopkinson et al, 1995), that the localization of BP180
in hemidesmosomes requires the integrin α6 subunit. Our results
published by Borradori et al (1997) and the coprecipitation studies
and yeast-two hybrid analyses by Schaapveld et al (1998) and Aho
and Uitto (1998), indicate that the interaction of BP180 with the
cytoplasmic domain of β4 contributes to the localization of BP180
in hemidesmosomes. This is further supported by recent transfection
experiments showing that the expression of the cytoplasmic domain
of β4 alone is sufficient to concentrate BP180 to the basal cell side of
cells at sites of cell substrate contact (Nievers et al, 1998).Nevertheless,
we fully agree with Jones et al that an additional interaction between
α6 and BP180 might contribute to the stabilization of hemides-
momes. This possibility has been discussed by our group (see also
Borradori and Sonnenberg, 1996).
The suggestion made by Hopkinson et al (1998) that the data
reported by Niessen et al (1996) contradicts those of Nievers et al
(1998) is blatantly incorrect. The authors refer to Fig 7(C, G) in the
paper by Nievers et al, which represents PA-JEB cells incubated with
rabbit α6Aantiserum andwith amonoclonal antibody againstBP180.
Both of these images do not show specific staining, only some back-
ground staining is observed. As indicated in the legend to Fig 7, the
expression of α6 in PA-JEB is heterogeneous and in general is weak.
Figure 7(C, G) are examples of cells in which the localization of the
α6 subunit in focal contacts could not be demonstrated. Thus, the
reasons leading Hopkinson et al to state that these results are different
from those provided by Niessen et al are not clear to us.
Another misinterpretation of our results occurs on the same page
(1020). It is suggested that based on our data, it could be predicted
that the integrin α6β4 heterodimer, containing a tail-less β4 subunit,
would not polarise BP180 to sites of cell-substrate contact in the
epidermis of mice, expressing such a mutated α6β4 integrin. This
assumptionwouldbevalid if the localizationofBP180 inhemidesmo-
somes would only be due to the interaction between BP180 and the
cytoplasmic domain of β4; however, like focal contact proteins, it
has become evident that the hemidesmosomal components can inter-
act in multiple ways with each other. For example, our previous
transfection experiments (Borradori et al, 1998), as well as recent
yeast-two hybrid analyses (Koster and Favre, unpublished observa-
tions) have indicated thatBP180can interactwithBP230. In addition,
BP180 has been found to bind to plectin (Aho and Uitto, 1997).
Thus, the localization of BP180 in hemidesmosomes is likely to be
facilitated by interactions with many proteins other than α6β4.
Finally, the interaction of BP180 with extracellular matrix compon-
ents, such as laminin-5 (Reddy et al, 1998), might also drive the
localization of this protein to the basal side of keratinocytes.
In our immortalized β4-deficient junctional epidermolysis bullosa
keratinocytes (PA-JEB cells), which produce laminin-5, we have
been unable to observe consistently the presence of BP180 in hemi-
desmosome-like structures; however, because laminin-5 is modified
in various ways (e.g., by proteolytic cleavage and by interaction
with other laminin isoforms), critically affecting its function in the
promotion of cell adhesion, it is possible that the inability of BP180
to become correctly polarised at the basal side in these PA-JEB cells
is due to incorrect processing of the synthesized laminin-5 molecules.
A direct comparison of these findings with the in vivo observation of
Murgia et al (1998) in a knockout mouse, expressing a β4 subunit
lacking its cytoplasmic domain, in which BP180 is correctly localized
at cell substrate contact sites is not allowed, because the conditions in
these two studies are obviously quite different. It is therefore not
correct to conclude that the data presented by Murgia et al (1998)
support the findings by Hopkinson et al (1998) and conflict with our
own results.
The authors offer an explanation for the fact that a chimeric β
subunit, containing the extracellular and transmembrane domains of
β4 and the cytoplasmic domain of β1, in association with α6 is unable
to localize a BP180 fragment, containing the extracellular region
identified by the authors to interact with α6, in focal contacts in
transfected COS-7 cells (Borradori et al, 1997). They assume that the
integrin α6 subunit is in a modified physiologic state, induced by the
chimeric β subunit, and is therefore no longer capable of binding
BP180. This possibility cannot be ruled out but seems somewhat
convoluted. First, it does not completely explain the impaired ability
of BP180 to become localized in hemidesmosome-like structures in
COS-7 cells, expressing a β4 mutant (β41,382) with a truncation of
the distal carboxy-terminal half of the β4 cytoplasmic domain, in
association with α6. This finding is reported in the same study in
which the experiments with the chimeric β subunit are presented,
but has been ignored by Hopkinson et al (1998). Second, it is not
consistent with ourfindings that in the cultured keratinocytes, lacking
β4, in which the α6 integrin subunit is associated with β1, α6 and
BP180 are not colocalized, but have distinct subcellular distributions
(Niessen et al, 1996; Schaapveld et al, 1998).
In summary, we feel that we have been incorrectly cited in the
paper by Hopkinson et al who have presented our results in an unfair
and selective manner to our discredit. We think that the scientific
community might be interested in our point of view.
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